Solaris Health Appoints Dr. Shawn H. Zimberg as National Director of Radiation Oncology Services

Appointment enhances access to expert specialty care for Solaris patients

Solaris Health Holdings, the nation’s leading provider of independent urological services, announced today that Shawn H. Zimberg, MD has been named National Director of Radiation Oncology Services.

Dr. Zimberg brings over 25 years of clinical expertise and management experience in radiation oncology to this new position at Solaris.

Dr. Zimberg is a leading authority in the development and management of radiation oncology practices as well as the optimization of financial and clinical efficiencies in multi-site and regional oncology facilities. Dr. Zimberg was a founding partner of, and is the Medical Director of Advanced Radiation Centers of New York (ARC), and serves on the board of the Association of Free-standing Radiation Oncology Centers (AFROC). Under his leadership ARC has become the largest freestanding radiation oncology practice in the Metro New York Tri-State Region, and has developed an infrastructure and service line that provides physics, dosimetry and IT support to oncology practices across the nation. Over his career, Dr. Zimberg has been at the forefront of deploying sophisticated radiation oncology technologies for brain, lung, head and neck, and prostate cancer treatments.

“The appointment of Dr. Zimberg is the next step in Solaris’ commitment to enhancing access to specialty and oncology-based healthcare,” said Eric Mason, MD, MBA, Solaris’ CEO. “Selecting a physician with Dr. Zimberg’s vast experience will help us standardize care and optimize patient outcomes throughout Solaris affiliated practices across the country, and will provide increased opportunities for growth in our oncology-related ancillary services” he said.

“I’m honored by the opportunity to join the Solaris Health management team,” Dr. Zimberg said. “Radiation is a critical weapon in the arsenal against prostate and other urologic cancers, and I look forward to contributing to Solaris’ development as a national radiation oncology platform predicated
forward to contributing to Solaris' development as a national radiation oncology platform predicated on innovation and clinical excellence.”

Source: Solaris Health
Published on: Tue, 15 Mar 2022